Presentation of ALS Survival Benefits at the 35th International Symposium on ALS/MND

CLNNW 12.06.2024

Full Press ReleaseSEC FilingsOur CLNNW Tweets

About Gravity Analytica

Recent News

  • 12.19.2024 - Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
  • 12.10.2024 - FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS
  • 12.06.2024 - Encore Presentation of RESTORE-ALS Trial Design at the 35th International Symposium on ALS/MND

Recent Filings

  • 12.20.2024 - 8-K Current report
  • 12.20.2024 - EX-99.1 EX-99.1
  • 12.10.2024 - 424B5 Prospectus [Rule 424(b)(5)]
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com